PTN.US Palatin Technologies, Inc. Common Stock

Healthcare Biotechnology USA Stocks
5.36 USD
Close of Nov 18, 2026
4.51 31.00
Market cap
USD 9.55M
P/E
-
P/B
1.63x
ROE
-998.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is PTN.US undervalued?

Graham number

The Graham number of Palatin Technologies, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Palatin Technologies, Inc. Common Stock fundamental analysis

No fundamental analysis for Palatin Technologies, Inc. Common Stock yet.

Palatin Technologies, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Palatin Technologies, Inc. Common Stock

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 f…

Full company profile